Scholarlink

<p>GLP-1 agonists, medications utilized in patients with obesity and type 2 diabetes, lead to significant weight reduction. Given that obesity is thought to contribute to the development and progression of hidradenitis suppurativa (HS), there is increasing interest in utilizing this medication in this patient population. This study aims to identify factors influencing GLP-1 agonist use in patients with HS. A retrospective review of patients diagnosed with HS who presented to Northwestern Medicine between October 2015 - December 2023 was completed. Statistical analyses, including Chi-squared tests and logistic regressions, were used to identify variables associated with GLP-1 agonist use in patients with HS. In addition to obesity (OR = 3.5, 95% CI = 2.9–4.3) and diabetes (OR = 5.8, 95% CI = 4.6–7.3), dyslipidemia (OR = 1.6, 95% CI = 1.3–2.1), hypertension (OR = 1.5, 95% CI = 1.2-2.0), and concomitant biologic use (OR = 1.5, 95% CI = 1.0-2.7) were all significantly associated with higher odds of being prescribed a GLP-1 agonist. Male sex (OR = 0.6, 95% CI = 0.5–0.8) and Non-Hispanic ethnicity (OR = 0.7, 95% CI = 0.5–0.9) were associated with decreased odds of GLP-1 agonist use. This study assesses factors associated with GLP-1 agonist use in patients with HS. In addition to emphasizing the importance of managing comorbidities, potential treatment disparities included lower prescription rates among male and Non-Hispanic patients. Further studies should examine clinical outcomes of patients with HS prescribed GLP-1 agonists.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A single-center retrospective study of GLP-1 agonist use in patients with hidradenitis suppurativa

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月18日

查看全文
  • Sawsan Alkhalili,
  • Rahwa Hailemichael,
  • Cloe Allen,
  • Sydney A. Martin,
  • Alecia Blaszczak,
  • Kelsey S. Flood,
  • Julia M. Riley

摘要

GLP-1 agonists, medications utilized in patients with obesity and type 2 diabetes, lead to significant weight reduction. Given that obesity is thought to contribute to the development and progression of hidradenitis suppurativa (HS), there is increasing interest in utilizing this medication in this patient population. This study aims to identify factors influencing GLP-1 agonist use in patients with HS. A retrospective review of patients diagnosed with HS who presented to Northwestern Medicine between October 2015 - December 2023 was completed. Statistical analyses, including Chi-squared tests and logistic regressions, were used to identify variables associated with GLP-1 agonist use in patients with HS. In addition to obesity (OR = 3.5, 95% CI = 2.9–4.3) and diabetes (OR = 5.8, 95% CI = 4.6–7.3), dyslipidemia (OR = 1.6, 95% CI = 1.3–2.1), hypertension (OR = 1.5, 95% CI = 1.2-2.0), and concomitant biologic use (OR = 1.5, 95% CI = 1.0-2.7) were all significantly associated with higher odds of being prescribed a GLP-1 agonist. Male sex (OR = 0.6, 95% CI = 0.5–0.8) and Non-Hispanic ethnicity (OR = 0.7, 95% CI = 0.5–0.9) were associated with decreased odds of GLP-1 agonist use. This study assesses factors associated with GLP-1 agonist use in patients with HS. In addition to emphasizing the importance of managing comorbidities, potential treatment disparities included lower prescription rates among male and Non-Hispanic patients. Further studies should examine clinical outcomes of patients with HS prescribed GLP-1 agonists.